{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:17:25Z","timestamp":1780319845294,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T00:00:00Z","timestamp":1222819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s10157-008-0066-1","type":"journal-article","created":{"date-parts":[[2008,6,24]],"date-time":"2008-06-24T06:25:53Z","timestamp":1214288753000},"page":"398-402","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib"],"prefix":"10.1007","volume":"12","author":[{"given":"Kohsuke","family":"Masutani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichiro","family":"Fujisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiro","family":"Toyonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Inoshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritsuko","family":"Katafuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hirakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,1]]},"reference":[{"key":"66_CR1","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","volume":"20","author":"M Ranson","year":"2002","unstructured":"Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol. 2002;20:2240\u201350.","journal-title":"J Clin Oncol"},{"key":"66_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","volume":"361","author":"A Inoue","year":"2003","unstructured":"Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137\u20139.","journal-title":"Lancet"},{"key":"66_CR3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.5858\/2005-129-1044-MTRTTU","volume":"129","author":"JS Truell","year":"2005","unstructured":"Truell JS, Fishbein MC, Figlin R. Myocarditis temporally related to the use of gefitinib. Arch Pathol Lab Med. 2005;129:1044\u20136.","journal-title":"Arch Pathol Lab Med"},{"key":"66_CR4","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1200\/JCO.2004.09.064","volume":"22","author":"R Kumasaka","year":"2004","unstructured":"Kumasaka R, Nakamura N, Shirato K, Osawa H, Takanashi S, Hasegawa Y, et al. Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy. J Clin Oncol. 2004;22:2504\u20135.","journal-title":"J Clin Oncol"},{"key":"66_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s10157-005-0370-y","volume":"9","author":"KK Lau","year":"2005","unstructured":"Lau KK, Santos NMD. Post-infectious acute glomerulonephritis with predominant mesangial deposition of IgA. Clin Exp Nephrol. 2005;9:262\u20133.","journal-title":"Clin Exp Nephrol"},{"key":"66_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1096\/fj.03-0702fje","volume":"18","author":"H Francois","year":"2004","unstructured":"Francois H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J. 2004;18:926\u20138.","journal-title":"FASEB J"},{"key":"66_CR7","first-page":"5054","volume":"63","author":"H Suzuki","year":"2003","unstructured":"Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res. 2003;63:5054\u20139.","journal-title":"Cancer Res"},{"key":"66_CR8","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006;24:2549\u201356.","journal-title":"J Clin Oncol"},{"key":"66_CR9","first-page":"565","volume":"41","author":"T Miya","year":"2003","unstructured":"Miya T, Ono Y, Tanaka H, Koshiishi Y, Goya T. Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report. Nihon Kokyuki Gakkai Zasshi. 2003;41:565\u20138. (Japanese).","journal-title":"Nihon Kokyuki Gakkai Zasshi"},{"key":"66_CR10","first-page":"F1191","volume":"255","author":"PR Goodyear","year":"1988","unstructured":"Goodyear PR, Kachra Z, Bell C, Rozen R. Renal tubular cells are potential targets for epidermal growth factor. Am J Physiol. 1988;255:F1191\u20136.","journal-title":"Am J Physiol"},{"key":"66_CR11","doi-asserted-by":"publisher","first-page":"17612","DOI":"10.1074\/jbc.274.25.17612","volume":"274","author":"S Gibson","year":"1999","unstructured":"Gibson S, Tu S, Oyer R, Anderson SM, Johnson GL. Epidermal growth factor protects epithelial cell against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem. 1999;274:17612\u20138.","journal-title":"J Biol Chem"},{"key":"66_CR12","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/j.1523-1755.2004.00955.x","volume":"66","author":"L Wassef","year":"2004","unstructured":"Wassef L, Kelly D, Gilbert RE. Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. Kidney Int. 2004;66:1805\u201314.","journal-title":"Kidney Int"},{"key":"66_CR13","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1046\/j.1523-1755.2003.00256.x","volume":"64","author":"VE Torres","year":"2003","unstructured":"Torres VE, Sweeney WE Jr, Wang X, Qian Q, Harris PC, Frost P, et al. EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SRPD rats. Kidney Int. 2003;64:1573\u20139.","journal-title":"Kidney Int"},{"key":"66_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10157-004-0324-9","volume":"8","author":"LYY Chan","year":"2004","unstructured":"Chan LYY, Leung JCK, Lai KN. Novel mechanisms of tubulointerstitial injury in IgA nephropathy: a new therapeutic paradigm in the prevention of progressive renal failure. Clin Exp Nephrol. 2004;8:297\u2013303.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-008-0066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-008-0066-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-008-0066-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-008-0066-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T02:18:21Z","timestamp":1659061101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-008-0066-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["66"],"URL":"https:\/\/doi.org\/10.1007\/s10157-008-0066-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]},"assertion":[{"value":"31 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}